<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615130</url>
  </required_header>
  <id_info>
    <org_study_id>1335/2020</org_study_id>
    <nct_id>NCT04615130</nct_id>
  </id_info>
  <brief_title>PUlmonary REhabilitation in Patients Suffering From Post-PE Syndrome</brief_title>
  <acronym>PURE-PE</acronym>
  <official_title>Investigation of Outpatient PUlmonary REhabilitation in Patients Suffering From Post-PE Syndrome: a Randomized Waitlist-controlled Trial - the PURE-PE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, parallel, randomized waitlist-controlled trial that primarily&#xD;
      focuses on the short-term benefit of outpatient pulmonary rehabilitation (PR) on patients&#xD;
      after acute pulmonary embolism.&#xD;
&#xD;
      Patients will be randomized into an intervention and a control group. The intervention group&#xD;
      will receive 6 weeks of outpatient PR, while patients in the other treatment arm will serve&#xD;
      as a control. After completion of the randomized study, the second arm will undergo PR as&#xD;
      well.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>As the control group will undergo rehabilitation after the study period as well, it is possible to blind patients and outcome assessors to the treatment group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>6-Minute Walk Test</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of walking distance covered within 6 minutes before and after the intervention/control period, measured in meters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peak oxygen consumption</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of peak oxygen uptake (VO2/kg/min) measured by lung spiroergometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal workload</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of maximal workload in cycle ergometer tests measured in Watt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-repetition maximum for lower extremities</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of one-repetition maximum for lower extremities measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-repetition maximum for upper extremities</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of one-repetition maximum for upper extremities measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal inspiratory muscle pressure</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change in maximum inspiratory muscle pressure measured in mbar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory muscle endurance</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change in inspiratory muscle endurance measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of dyspnea</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change in dyspea at rest and maximal exertion mesured with the medical research council scale and BORG scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of quality of life measured with the 5-level EQ-5D version (EQ-5D-5L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease related quality of life</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of quality of life measured with the Pulmonary Embolism Quality of Life (PEmb-QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional limitations</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of functional status measured with the patient reported outcomes measurement information system (PROMIS) physical function short form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change of functional status measured with the post-VTE functional status scale (min: 0, max: 4, lower scores indicate better functional status)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>within the 6-week study period</time_frame>
    <description>change in anxiety and depression measured with the hospital anxiety and depression scale (HADS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo 6 weeks of outpatient rehabilitation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive no intervention throughout the 6 weeks period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rehabilitation</intervention_name>
    <description>Rehabilitation, exercise training</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post-PE syndrome (except patients previously diagnosed with CTEPH) diagnosed by any of&#xD;
             the following:&#xD;
&#xD;
               -  Post-PE functional impairment criteria&#xD;
&#xD;
               -  Post-PE Cardiac Impairment criteria&#xD;
&#xD;
               -  Chronic Thromboembolic Disease criteria&#xD;
&#xD;
          -  Possibility of starting rehabilitation between 12 and 24 weeks after the initial event&#xD;
             of PE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CTEPH diagnosis&#xD;
&#xD;
          -  Chronic pulmonary diseases: COPD, interstitial lung diseases, asthma (only patients&#xD;
             with severe asthma defined as a FEV1 â‰¤ 80% will be excluded)&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Myocardial infarction or cardiac surgery one year prior to inclusion&#xD;
&#xD;
          -  Congenital heart disease, congestive heart failure&#xD;
&#xD;
          -  History of stroke&#xD;
&#xD;
          -  Any previous inpatient or outpatient PR&#xD;
&#xD;
        Additional criteria that are absolute contraindications for pulmonary rehabilitation&#xD;
&#xD;
          -  Acute and decompensated disease states with severe functional restrictions of various&#xD;
             organ systems (e.g. heart, kidney and liver insufficiency, unstable angina pectoris,&#xD;
             hemodynamically unstable arrhythmias, acute spinal cord injury, untreated hormonal&#xD;
             disorders, acute psychological disorders)&#xD;
&#xD;
          -  open tuberculosis&#xD;
&#xD;
          -  active infectious diseases and acute inflammatory processes&#xD;
&#xD;
          -  Stressful and time-consuming therapy that significantly impair the ability to&#xD;
             rehabilitate (e.g. chemotherapy or radiation therapy after malignancy)&#xD;
&#xD;
          -  Participants who are not sufficiently resilient due to physical or mental impairment&#xD;
             and / or cannot be mobilized and therefore cannot actively use the rehabilitation&#xD;
             facility&#xD;
&#xD;
          -  lack of motivation for therapy&#xD;
&#xD;
          -  massive incontinence&#xD;
&#xD;
          -  drugs and alcohol addiction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephan Nopp, Dr.</last_name>
    <phone>+43 40400 44170</phone>
    <email>stephan.nopp@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Therme Wien Med</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Nopp, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Stephan Nopp</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Rehabilitation</keyword>
  <keyword>Exercise Training</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04615130/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

